Takamatsu Yasushi, Jimi Shiro, Sato Tomohito, Hara Shuuji, Suzumiya Junji, Tamura Kazuo
First Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Transfusion. 2007 Jan;47(1):41-9. doi: 10.1111/j.1537-2995.2007.01061.x.
Granulocyte-colony-stimulating factor (G-CSF) is used for hematopoietic progenitor cell (HPC) mobilization. Platelet (PLT) counts decrease during G-CSF administration. The mechanisms have not been determined, however. Because splenic pooling of PLTs caused thrombocytopenia in patients with splenomegaly and splenic enlargement was observed in G-CSF-treated donors, it was hypothesized that hypersplenism might cause G-CSF-induced thrombocytopenia.
Mice were treated with several concentrations of G-CSF, and PLT count was measured. Because transfused PLTs should be cleared rapidly from the blood stream under hypersplenic state, PLT life span was studied. To determine direct role of spleen on thrombocytopenia, G-CSF was given to splenectomized mice. Because PLT count did not decrease in G-CSF-expressing transgenic mice, G-CSF was given to mice for a longer period of time and PLT count was investigated.
PLT counts decreased while spleen weight increased in a dose-dependent manner by G-CSF treatment. No significant difference in PLT life span was found between G-CSF-treated and control mice. Histologic analysis showed no significant increase in PLT numbers trapped in either spleen or other tissue after PLT transfusion in G-CSF-treated mice. In splenectomized mice as well as in normal mice, G-CSF caused thrombocytopenia. When G-CSF was given to mice for a longer period of time, PLT counts decreased during the first 7 days and thereafter began to increase followed by returning to baseline on Day 15.
Thrombocytopenia coincided with splenomegaly during G-CSF treatment, but hypersplenism was not responsible for thrombocytopenia. G-CSF-induced thrombocytopenia was a transient event and improved spontaneously despite continual G-CSF treatment.
粒细胞集落刺激因子(G-CSF)用于造血祖细胞(HPC)动员。在给予G-CSF期间血小板(PLT)计数会下降。然而,其机制尚未明确。由于脾肿大患者中血小板的脾池化会导致血小板减少,且在接受G-CSF治疗的供体中观察到脾脏增大,因此推测脾功能亢进可能导致G-CSF诱导的血小板减少。
用几种浓度的G-CSF处理小鼠,并测量PLT计数。由于在脾功能亢进状态下输入的血小板应迅速从血流中清除,因此研究了血小板寿命。为了确定脾脏在血小板减少中的直接作用,对脾切除的小鼠给予G-CSF。由于表达G-CSF的转基因小鼠的PLT计数未降低,因此对小鼠给予更长时间的G-CSF并研究PLT计数。
通过G-CSF治疗,PLT计数下降,而脾脏重量呈剂量依赖性增加。G-CSF治疗组和对照组小鼠的血小板寿命无显著差异。组织学分析显示,G-CSF治疗组小鼠在输入血小板后,脾脏或其他组织中滞留的血小板数量无显著增加。在脾切除的小鼠以及正常小鼠中,G-CSF均导致血小板减少。当对小鼠给予更长时间的G-CSF时,PLT计数在最初7天内下降,此后开始增加,随后在第15天恢复到基线水平。
G-CSF治疗期间血小板减少与脾肿大同时出现,但脾功能亢进并非血小板减少的原因。G-CSF诱导的血小板减少是一个短暂事件,尽管持续给予G-CSF治疗,仍可自发改善。